Rudek MA - Search Results

1

Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.

Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. Cianfrocca M, et al. Among authors: rudek ma. J Clin Oncol. 2002 Jan 1;20(1):153-9. doi: 10.1200/JCO.2002.20.1.153. J Clin Oncol. 2002. PMID: 11773164 Clinical Trial.

2

High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma.

Rudek MA, March CL, Bauer KS Jr, Pluda JM, Figg WD. Rudek MA, et al. J Pharm Biomed Anal. 2000 Jul;22(6):1003-14. doi: 10.1016/s0731-7085(00)00257-0. J Pharm Biomed Anal. 2000. PMID: 10857569

3

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.

Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Rudek MA, et al. J Clin Oncol. 2001 Jan 15;19(2):584-92. doi: 10.1200/JCO.2001.19.2.584. J Clin Oncol. 2001. PMID: 11208854 Clinical Trial.

4

Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.

Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Rudek MA, et al. Am J Hematol. 2001 May;67(1):51-3. doi: 10.1002/ajh.1076. Am J Hematol. 2001. PMID: 11279658 Free article.

5

Drug-induced lupus associated with COL-3: report of 3 cases.

Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Ghate JV, et al. Among authors: rudek ma. Arch Dermatol. 2001 Apr;137(4):471-4. Arch Dermatol. 2001. PMID: 11295928 Clinical Trial.

6

Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?

Rudek MA, Venitz J, Figg WD. Rudek MA, et al. Pharmacotherapy. 2002 Jun;22(6):705-20. doi: 10.1592/phco.22.9.705.34062. Pharmacotherapy. 2002. PMID: 12066962 Review.

7

Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.

Rudek MA, Venitz J, Ando Y, Reed E, Pluda JM, Figg WD. Rudek MA, et al. J Clin Pharmacol. 2003 Oct;43(10):1124-35. doi: 10.1177/0091270003256675. J Clin Pharmacol. 2003. PMID: 14517195

8

Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.

Rudek MA, Bauer KS Jr, Lush RM 3rd, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD. Rudek MA, et al. Ann Pharmacother. 2003 Oct;37(10):1369-74. doi: 10.1345/aph.1C404. Ann Pharmacother. 2003. PMID: 14519054 Clinical Trial.

9

Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial.

Cianfrocca M, Lee S, Von Roenn J, Rudek MA, Dezube BJ, Krown SE, Sparano JA. Cianfrocca M, et al. Among authors: rudek ma. Cancer Chemother Pharmacol. 2011 Oct;68(4):827-33. doi: 10.1007/s00280-010-1509-4. Epub 2011 Jan 5. Cancer Chemother Pharmacol. 2011. PMID: 21207228 Free PMC article. Clinical Trial.

10

The rising challenge of non-AIDS-defining cancers in HIV-infected patients.

Deeken JF, Tjen-A-Looi A, Rudek MA, Okuliar C, Young M, Little RF, Dezube BJ. Deeken JF, et al. Among authors: rudek ma. Clin Infect Dis. 2012 Nov;55(9):1228-35. doi: 10.1093/cid/cis613. Epub 2012 Jul 9. Clin Infect Dis. 2012. PMID: 22776851 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters